Cancer Anorexia-Cachexia Syndrome (CACS) Market Report 2026

The cancer anorexia-cachexia syndrome (cacs) market size has grown rapidly in recent years. It will grow from $3.88 billion in 2025 to $4.29 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing prevalence of advanced cancer cases, growing recognition of cachexia impact on treatment outcomes, early clinical use of appetite stimulants, rising hospital-based supportive care programs, expansion of oncology nutrition research.

The cancer anorexia-cachexia syndrome (cacs) market size is expected to see rapid growth in the next few years. It will grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing investments in cachexia drug development, growing focus on personalized oncology supportive care, rising clinical trial activity for novel agents, expansion of home-based cancer care, increasing integration of cachexia management in oncology protocols. Major trends in the forecast period include increasing development of targeted cachexia therapies, rising focus on anti-inflammatory treatment pathways, growing adoption of combination therapeutic approaches, expansion of nutritional and metabolic support solutions, enhanced emphasis on early cachexia intervention.

The rising prevalence of cancer is expected to drive the growth of the cancer anorexia-cachexia syndrome market in the coming years. Cancer is a broad category of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The global incidence of cancer is increasing due to factors such as an aging population, changes in lifestyle, environmental exposures, advances in detection techniques, greater awareness, and the influence of genetic predispositions and infections associated with certain cancers. Cancer anorexia-cachexia syndrome (CACS) addresses the increasing burden of cancer by targeting severe weight loss and malnutrition commonly experienced by cancer patients, thereby enhancing their overall quality of life and improving treatment outcomes. For example, in August 2024, a report published by Macmillan Cancer Support, a UK-based charitable organization, stated that more than 3 million people in the UK are living with cancer, with projections indicating this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the growing prevalence of cancer is fueling the expansion of the cancer anorexia-cachexia syndrome market.

Rising healthcare expenditure is anticipated to drive the growth of the cancer anorexia-cachexia syndrome market in the coming years. Healthcare expenditure refers to the overall financial resources allocated to healthcare services, encompassing both public and private sector spending. The growth in healthcare expenditure is fueled by factors such as an aging population, the increasing burden of chronic diseases, advancements in medical technologies, and growing demand for high-quality healthcare services. Cancer Anorexia-Cachexia Syndrome (CACS) contributes to higher healthcare spending due to the need for specialized therapies, nutritional interventions, and palliative care for affected patients, thereby increasing the costs associated with managing cancer-related complications. For example, in May 2024, data from the Office for National Statistics, a UK-based government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, representing a notable rise compared to the 0.9% growth recorded in 2022. Consequently, the rise in healthcare expenditure is supporting the expansion of the cancer anorexia-cachexia syndrome market.

Leading companies in the cancer anorexia-cachexia syndrome market are prioritizing the development of advanced therapies, including monoclonal antibodies, to improve treatment effectiveness, enhance patient outcomes, and meet unmet clinical demands. Monoclonal antibody therapies involve the use of lab-engineered antibodies that specifically bind to target antigens on cancer cells, enabling the immune system to better identify and combat them. For example, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, reported favorable results from a Phase II clinical trial of ponsegromab, a monoclonal antibody designed to inhibit Growth/Differentiation Factor 15 (GDF-15). The encouraging findings from this study highlight a promising new therapeutic option for patients affected by this severe condition, for which limited effective treatments are currently available. The Phase II trial outcomes indicate meaningful advancement in targeting the inflammatory mechanisms responsible for muscle wasting and weight loss in cancer patients. This therapeutic strategy seeks not only to restore physical strength but also to improve overall quality of life, representing a significant milestone in cancer care.

Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer anorexia-cachexia syndrome (cacs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cancer anorexia-cachexia syndrome market by increasing costs of imported active pharmaceutical ingredients, biologics, formulation excipients, and specialized manufacturing equipment used in drug development and production. North America and Europe are most affected due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces cost pressures related to raw material imports. These tariffs are increasing production costs and influencing pricing strategies for novel therapies. However, they are also encouraging localized manufacturing, regional sourcing of ingredients, and long-term investments in domestic pharmaceutical production capabilities.

The cancer anorexia-cachexia syndrome (cacs) market research report is one of a series of new reports that provides cancer anorexia-cachexia syndrome (cacs) market statistics, including cancer anorexia-cachexia syndrome (cacs) industry global market size, regional shares, competitors with a cancer anorexia-cachexia syndrome (cacs) market share, detailed cancer anorexia-cachexia syndrome (cacs) market segments, market trends and opportunities, and any further data you may need to thrive in the cancer anorexia-cachexia syndrome (cacs) industry. This cancer anorexia-cachexia syndrome (cacs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer anorexia-cachexia syndrome (CACS) is a complex condition frequently observed in cancer patients and is characterized by profound metabolic abnormalities. It results from a combination of inflammatory processes, hormonal imbalances, and disrupted nutrient metabolism, which often contribute to poor clinical outcomes and reduced responsiveness to treatment.

The primary indications of cancer anorexia-cachexia syndrome (CACS) include weight loss prevention, loss of appetite, muscle wasting, inflammation, and others. Weight loss prevention in CACS focuses on preserving body weight and lean muscle mass by improving nutritional intake and addressing cancer-related metabolic dysfunction. These needs are managed using a range of therapeutic options, such as corticosteroids, combination therapies, and others. Treatment approaches work through mechanisms including appetite stimulation, anti-inflammatory action, hormonal modulation, cannabinoids, and other pathways. These therapies are delivered via multiple routes of administration, including oral, intravenous, subcutaneous, transdermal, and others, and are utilized across various settings such as hospitals, clinics, and home care environments.

The cancer anorexia-cachexia syndrome (CACS) market consists of revenues earned by entities by providing services such as nutritional support, pharmacological treatments, palliative care, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.